Market Sector Leaders
Gregory Frost, Ph.D. – Senior Vice President, Health Sector
Dr. Frost brings more than 20 years of biotechnology industry and research experience in the areas of biochemistry, molecular pathology, pharmacology, and drug delivery. Previously, Dr. Frost was the Chief Executive Officer of Halozyme Therapeutics, a company he co-founded in 1999, and has also served on the Board of Directors and in numerous operational roles, including Chief Scientific Officer. For more than 15 years, Dr. Frost led the research and development efforts at Halozyme from discovery through commercialization for a number of internal and partnered biotechnology products, as well as facilitating broad alliances with pharmaceutical companies such as Roche and Pfizer.
Before co-founding Halozyme, Dr. Frost conducted research at the Sidney Kimmel Cancer Center. Prior to that, while in the Department of Pathology at the University of California, San Francisco, Dr. Frost led foundational studies to purify, clone, and characterize an enzyme gene family of human hyaluronidases. He is an inventor in several key patents and has published multiple peer-reviewed articles in the hyaluronidase field.
Dr. Frost is a member of the American Association for Cancer Research and the American Society of Clinical Oncology and a board member of BIOCOM, a life science industry organization based in Southern California. Dr. Frost received a B.A. in biochemistry and molecular biology from the University of California, Santa Cruz, and a Ph.D. in the Department of Pathology at the University of California, San Francisco.
Thomas R. Kasser, Ph.D. – Senior Vice President, Food Sector
Dr. Kasser brings over 25 years of business management experience in the biotechnology and life sciences industries. He was most recently President and Chief Executive Officer of Angionics, Inc., an early-stage biotech company focused on novel anti-angiogenic technology directed at therapies for cancer and ocular diseases.
Prior to Angionics, he was a Covance Corporate Vice President and General Manager of Covance Research Products. Dr. Kasser had over 20 years of experience at Monsanto Company both in commercial as well as scientific leadership roles, including tenures as General Manager of Monsanto Choice Genetics, directing new product development for the Nutrition and Consumer products business, and managing clinical safety and efficacy trials under the jurisdiction of the FDA Center for Veterinary Medicine.
Dr. Kasser was designated a Monsanto Fellow in recognition of his scientific and technical excellence. He currently serves on the Board of Directors for AquaBounty Technologies, Inc., a biotechnology company focused on enhancing productivity in aquaculture. Dr. Kasser received his Ph.D. in Nutrition from the University of Georgia and an M.S. in Animal Nutrition from the Pennsylvania State University. He also received an M.B.A. from Washington University - St. Louis.
Robert F. Walsh, III – Senior Vice President, Energy Sector
Mr. Walsh joins Intrexon with more than 30 years of global petroleum and chemical industry experience, including 26 years at Royal Dutch Shell. Most recently, Mr. Walsh was Chief Commercial Officer of ZeaChem, Inc., a private industrial biotechnology company developing a cellulose-based bio-refinery platform capable of producing advanced fuels and chemicals.
Previously, Mr. Walsh was CEO and Executive Board member of Aurora Biofuels, Inc., a private industrial biotechnology company developing algae based alternative fuels and animal protein. He was also President and Executive Board Member of LS9, Inc., a private industrial biotechnology company developing biofuels using synthetic biology. Under his leadership, the World Economic Forum honored LS9 as a 2007 Technology Pioneer.
At Shell, Mr. Walsh held senior manufacturing, supply, distribution, and strategic planning positions in North America and Europe, including General Manager Supply-Europe for Shell Europe Oil Products.
He earned his B.S. in Chemical Engineering from Purdue University.
Nir Nimrodi – Senior Vice President, Environment Sector
Mr. Nimrodi brings to Intrexon over 20 years of diverse international experience, in large global businesses in the life sciences, pharmaceutical, biotechnology, and diagnostics industries. Prior to joining Intrexon, Mr. Nimrodi was most recently the Vice President and General Manager of Life Technologies, Inc. Food Safety and Animal Health Business, now part of Thermo Fisher Scientific, and also served in numerous executive roles, including Chief Executive Officer and Board Member of Life Technologies Israel and Head of Protein Technologies. While at Life Technologies, he played a key part in its growth, culminating in its recent acquisition, which represents the largest transaction to-date for this space at $13.6 billion.
Previously, Mr. Nimrodi held leadership positions as CEO of Proneuron Biotechnologies, Inc. and also Mindsense Biosystems, as well as Director of Finance of Teva Pharmaceutical Industries, Ltd. Before joining the life sciences industry, he served in the Israeli Navy and worked for the Israeli Ministry of Defense.
Mr. Nimrodi earned a B.A. in Economics and an M.B.A in Finance from Tel-Aviv University.
Kelly Huang, Ph.D. – Senior Vice President, Consumer Sector
Dr. Huang brings to Intrexon over 18 years experience leading global businesses in life sciences and consumer healthcare through integration of scientific, consumer, and professional insights to create value by putting the customer and patient at the center. Before joining Intrexon, Dr. Huang was President of HealthTronics, a subsidiary of Endo Health Solutions, and Executive Committee Member of Endo where he contributed to strategic leadership across multiple sectors since 2011. To advance Endo’s solutions strategy, he broadened HealthTronics beyond surgical services into healthcare informatics through strategic acquisitions and development of analytics capabilities.
Formerly, Dr. Huang spent a significant 16-year tenure with the Johnson & Johnson Family of Companies. From 2009 through 2011, he led award winning product launches in cosmetic and over-the-counter consumer products as Vice President of Research & Development and corporate officer of Neutrogena Corporation, a J&J company. As Vice President with J&J’s Development Corporation from 2006 through 2009, Dr. Huang also established and headed an Internal Venture to partner with a synthetic biology company towards development of a transformational delivery platform based upon novel protein conjugates. In addition, he held leadership positions within J&J’s Consumer Healthcare business, which included spending two years in Paris, France, that drove innovation globally.
Dr. Huang earned a B.S. in Chemical Engineering from the University of Massachusetts, followed by an M.S. and Ph.D. in Chemical Engineering from Stanford University. He advises Spindletop Capital and is a member of the board of HealthTronics Information Technology Solutions with Altaris Capital. Dr. Huang is a member of the National Association of Corporate Directors.
Peter Seufer-Wasserthal, Ph.D. – Vice President, Business Development, Europe and Asia
Dr. Seufer-Wasserthal brings more than 20 years of experience in business development and licensing, as well as enzyme technology and chemistry, to Intrexon.
Prior to joining Intrexon, Dr. Seufer-Wasserthal was Senior Vice President of Pharmaceuticals at Codexis, Inc., where he was responsible for closing numerous licensing, research and supply agreements, and adapting IP strategy to increase account penetration. Before Codexis, Inc., Dr. Seufer-Wasserthal managed drug discovery collaborations, licensed pre-clinical candidates and purchased services for drug development projects as Senior Vice President of Clinical Development at Morphochem AG.
He holds a Ph.D. in organic chemistry from the Technical University of Graz.